Meritage Portfolio Management Decreases Stake in United Therapeutics Corporation $UTHR

Meritage Portfolio Management decreased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 3.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,473 shares of the biotechnology company’s stock after selling 57 shares during the period. Meritage Portfolio Management’s holdings in United Therapeutics were worth $423,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CWM LLC increased its stake in United Therapeutics by 204.3% in the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock valued at $1,492,000 after buying an additional 3,487 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in United Therapeutics by 16.7% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 8,184 shares of the biotechnology company’s stock valued at $2,352,000 after buying an additional 1,170 shares during the last quarter. Concurrent Investment Advisors LLC increased its stake in United Therapeutics by 18.6% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 874 shares of the biotechnology company’s stock valued at $251,000 after buying an additional 137 shares during the last quarter. Blue Trust Inc. increased its stake in United Therapeutics by 7.5% in the 2nd quarter. Blue Trust Inc. now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after buying an additional 86 shares during the last quarter. Finally, Galvin Gaustad & Stein LLC increased its stake in United Therapeutics by 21.6% in the 2nd quarter. Galvin Gaustad & Stein LLC now owns 37,086 shares of the biotechnology company’s stock valued at $10,657,000 after buying an additional 6,598 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Up 0.0%

UTHR opened at $440.06 on Tuesday. The company has a 50 day moving average of $375.22 and a 200 day moving average of $324.71. The company has a market cap of $19.85 billion, a PE ratio of 17.18, a price-to-earnings-growth ratio of 4.82 and a beta of 0.66. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $459.48.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The business had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm’s quarterly revenue was up 11.7% on a year-over-year basis. During the same period last year, the business posted $5.85 earnings per share. Research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares of the company’s stock, valued at $11,356,133.75. This trade represents a 23.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total transaction of $9,396,900.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 261,935 shares of company stock valued at $105,561,472. 10.30% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on UTHR. HC Wainwright raised their price target on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a “buy” rating in a research note on Friday, September 5th. Jefferies Financial Group raised their price target on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Wells Fargo & Company raised their price target on shares of United Therapeutics from $295.00 to $414.00 and gave the stock an “equal weight” rating in a research note on Wednesday, September 3rd. Bank of America raised their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. Finally, Royal Bank Of Canada began coverage on shares of United Therapeutics in a research note on Friday, September 26th. They set an “outperform” rating and a $569.00 price target for the company. Ten investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $457.21.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.